PMID 34324435 describes a one-clinic retrospective chart review followed by telephone questions. Seventeen charts were identified, 16 people were reached, 12 had received BPC-157 alone, and four had received BPC-157 plus thymosin beta-4 (TB4). Most respondents recalled less knee pain, but there was no concurrent control or random assignment. The paper requested recalled zero-to-ten pain ratings without reporting paired scores or a prespecified responder rule, and its duration counts are internally inconsistent. This small uncontrolled report does not establish that BPC-157 caused improvement, repaired tissue, outperformed another intervention, or is generally safe.[1][2]
Study at a glance
| Field | Study record |
|---|---|
| Research question | What did patients at one wellness clinic report after a knee-joint procedure involving BPC-157 alone or BPC-157 plus TB4? |
| Design | Retrospective 2019–2020 chart review with a later telephone survey; uncontrolled and unblinded |
| Population | 17 charts; 16 respondents; reported mean age about 60 years and range 19–77; mixed or incompletely established causes of knee pain |
| Exposure | 12 respondents had BPC-157 alone and four had BPC-157 plus TB4; two patients had repeat BPC-157 procedures after reinjury |
| Comparator | None; the two exposure groups were not randomized comparative arms |
| Follow-up | Variable; most procedures had occurred about six to 12 months before the survey, not at uniform scheduled study visits |
| Outcomes | Recalled pain change and duration; subjective mobility, exercise tolerance, stair use, sleep, and adverse-event questions |
| Registration | No public trial-registration identifier, dated protocol, or statistical analysis plan is reported in the article |
| Publication | Lee and Padgett, Alternative Therapies in Health and Medicine, 2021;27(4):8–13; PMID 34324435 |
| Commercial context | Patients paid the clinic for material and procedures; the authors declared no conflicts; no separate funding statement was reported |
This record concerns a historical study, not preparation, administration, or self-use guidance. The study-reading guide explains why a response proportion and a controlled treatment effect answer different questions.
What the review actually did
Investigators reviewed records from one Orlando clinic for people who had received a knee-joint procedure involving BPC-157 during 2019 through June 2020. A college student volunteering in the office telephoned patients later. Patients were asked to rate pain before and after the procedure from zero to ten, then describe mobility, exercise tolerance, stair use, sleep, and adverse events.[1]
The report therefore did ask numerical pain questions. However, it does not publish a complete set or analysis of paired pain ratings, standardized questionnaire administration, a named validated function or quality-of-life questionnaire, or a prespecified definition of improvement. Recalling a baseline after an intervention is different from recording it prospectively.
This is not a prospective randomized trial. Respondents knew what had occurred, and the paper does not report masked assessment. Selection, expectation, recall, interviewer, and reporting biases could influence the response proportion. Symptoms can also change through natural fluctuation, regression toward the mean, altered activity, other care, or procedural attention. A concurrent control and appropriate masking would address questions that this design cannot resolve.
Participant flow and mixed diagnoses
Seventeen people appeared in the charts and one could not be reached, leaving 16 in the telephone results. The paper does not identify the unreachable person's exposure group or outcome, and reports no missing-outcome sensitivity analysis. The 14 reported improvements are among the 16 contacted people, not a complete outcome assessment of all 17 charts.[1][2]
The respondents included nine women and seven men. Only four had a pre-procedure knee MRI: two had a meniscal tear, one an anterior cruciate ligament tear, and one popliteal bursitis; one meniscal case also had a medial collateral ligament sprain. Five respondents said another clinician had diagnosed knee osteoarthritis, but uniform imaging and diagnostic criteria were not supplied. The authors acknowledged that the group did not share one confirmed disorder. The pooled proportion cannot be treated as a diagnosis-specific result.
Keep BPC-157-only and combination charts separate
Among the 12 BPC-157-only respondents, 11 were classified as improved and one as not improved. Among the four who received BPC-157 plus TB4, three were classified as improved and one as not improved. The pooled total was 14/16, or 87.5%.[1][2]
The combination cases cannot estimate BPC-157's isolated contribution. They also are not a valid comparison against the BPC-157-only cases: the clinic used the combination earlier and then changed practice, assignment was not randomized, the groups were only 12 and four people, and diagnosis and exposure details varied. Two patients underwent repeat BPC-157 procedures after reinjury. This was not a uniform single-exposure cohort.[1]
The paper uses the phrase “significant improvement,” but supplies no hypothesis test, confidence interval, paired pain-score analysis, or prespecified responder rule for it. “Significant” is a descriptive label here, not demonstrated statistical significance. Neither the group proportions nor the variable exposures establish comparative benefit or a dose-response relationship.
Duration counts cannot be cleanly reconciled
Tables 4 and 5 distribute duration categories across all 12 BPC-157-only and all four combination respondents, despite the earlier improvement counts of 11 and three. Table 4 places a 24-hour response in the BPC-157-only group, whereas the discussion describes the temporary 24-hour response as a combination case. The discussion also gives nine of ten improving beyond three months and seven of eight beyond six months without a transparent derivation of those denominators.[1]
These discrepancies are not resolved in the accessible report. The duration categories should not be reconstructed into a reliable sustained-response rate, assumed to represent the same patients at fixed visits, or used to claim benefit lasting six or 12 months. Variable recall, repeat procedures, and no concurrent control further limit interpretation.
The paper displays mobility improvement for 75% and sleep improvement for 62.5%. These were informal retrospective reports, not results from a specified validated function, sleep, or quality-of-life instrument. The report provides no objective testing to corroborate them.[1]
No evidence of structural repair or comparative benefit
Four pre-procedure MRIs identified abnormalities, but the paper reports no follow-up imaging or other structural measurement. Symptom change cannot demonstrate cartilage growth or healing of a meniscal or ligament tear. Statements about tissue repair, surgery prevention, and advantages over steroid injections extend beyond what this study measured.[1]
There was no steroid, physical-therapy, saline, usual-care, or untreated control. The paper says no one received physical therapy after the procedure, but provides no complete account of analgesics, activity changes, other care, or conditions over follow-up. It cannot establish superiority to another intervention.
Harms were not assessed rigorously
Respondents were asked about adverse events, and the authors said none were noted. The report does not describe a prospective monitoring schedule, event dictionary, severity grading, laboratory surveillance, adjudication, or systematic long-term safety follow-up. Sixteen contacted people cannot characterize uncommon or delayed harms, and combination exposures complicate attribution.[1]
The distinction between adverse-event reporting and a comprehensive safety assessment matters. FDA's May 11, 2026 briefing memorandum, prepared for the July advisory meeting, included this paper among small human reports and concluded that clinical safety information was insufficient to characterize BPC-157 free base or acetate. It also discussed potential immunogenicity, aggregation, and peptide-related impurity concerns. These are broader assessments, not events demonstrated in the 16-person sample.[3][4]
Material identity and source limits
The paper names Tailor Made Compounding and describes a phosphate-buffered formulation containing benzyl alcohol. It does not provide a lot number, certificate of analysis, validated sequence assay, counterion identification, impurity profile, aggregation assessment, measured concentration verification, stability dataset, or sterility test report. A formulation description is not independent confirmation of those attributes.[1]
FDA distinguishes BPC-157 free base from BPC-157 acetate and notes inconsistent substance naming and characterization in the nominations. The knee paper does not resolve the form used. The free-base, salt, and counterion guide explains why a shared short name does not make those fields interchangeable.[3]
The co-exposure is called TB4 in the paper, but the report does not supply lot-level sequence confirmation for it. This summary does not silently relabel that material as a marketed TB-500 product. Neither name authenticates a catalog vial or transfers the study to another formulation, concentration, supplier, route, blend, or lot.
Registration, funding, and publication checks
No public prospective registration identifier, dated protocol, or analysis plan is supplied by the paper, and none was obtained for this exact chart review. That is a source-access and reporting limit, not proof that no private plan ever existed. The page does not certify prespecification, complete outcome reporting, or prospective safety monitoring. The registration and analysis-plan guide explains the distinction.
Patients paid the clinic for the experimental material and procedures. The clinic physician is an author; the authors declared no conflicts of interest in authorship or publication. No separate funding statement for the analysis or publication was found in the complete article. Those facts warrant transparent reporting but do not by themselves prove that the results were distorted.[1]
On September 3, 2026, the official PubMed metadata contained no linked CommentsCorrections relationship, and a separate rendered PubMed review found no visible linked correction, retraction, or expression-of-concern notice. Those are dated observations of this record, not an exhaustive guarantee that no notice exists elsewhere or will appear later.[2]
Dated FDA context is not a knee-treatment approval
The FDA meeting page identifies ulcerative colitis as the evaluated use for BPC-157 free base and acetate. The May 11 memorandum says the nominations had been withdrawn and FDA was evaluating both forms on its own initiative. It states that neither was a component of an FDA-approved drug at the time of that evaluation. Staff proposed against inclusion on the 503A Bulks List.[3][5][6]
The 68-page briefing and 149-page July 23 presentation file are different documents. The briefing's cover expressly distinguishes background advice from a final determination, and the meeting page describes advisory recommendations as nonbinding. These materials do not constitute a final compounding rule, a committee vote report, or approval of the knee procedure.[3][5][6]
At this page's September 3 source check, FDA listed BPC-157 in the withdrawn-nominations section of its safety-risk page, not its current Category 2 table. The risk statement retained limited safety-information, immunogenicity, impurity, and active-ingredient-characterization concerns.[4] For context, see how to check dated FDA status and distinguish an approved drug from research material.
Statistical significance, effect, uncertainty, and importance
- Statistical significance: no inferential comparison or confidence interval was reported for the telephone response proportions.
- Observed result: 11/12 BPC-157-only respondents and 3/4 combination respondents were categorized as improved; pooled 14/16 is not a controlled treatment effect.
- Uncertainty: one unreachable person, tiny nonrandom groups, mixed diagnoses, retrospective recall, missing paired ratings, an undefined responder rule, inconsistent duration counts, and variable follow-up.
- Clinical importance: less pain could matter to a patient, but this report does not reliably establish its magnitude, durability, causal attribution, structural consequences, comparative benefit, or balance against harms.
What this study does not prove
PMID 34324435 does not prove that BPC-157 treats knee pain, osteoarthritis, a meniscal injury, a ligament injury, bursitis, or another diagnosis. It does not demonstrate tissue regeneration, cartilage growth, prevention of surgery, superiority to steroid injection or physical therapy, or durable benefit. Its uncontrolled reports are hypothesis-generating rather than causal confirmation.[1][2]
It also does not establish comprehensive safety or validate a compounded, blended, or catalog material. Exact identity, formulation, impurities, aggregation, stability, sterility, and lot-specific attributes require their own evidence.
Frequently asked questions
How many people contributed results?
Seventeen charts were identified, but only 16 people were reached by telephone and included in the reported outcome totals. The unreachable person's result is unknown.[1][2]
How many received BPC-157 without TB4?
Twelve respondents had BPC-157-only records, and 11 were categorized as improved. Four others received BPC-157 plus TB4; three were categorized as improved. The groups were not randomized comparisons.[1]
Was there a placebo or usual-care control?
No. The review cannot separate a treatment effect from symptom fluctuation, expectation, recall, other care, or regression toward the mean.
Did “significant improvement” mean statistically significant?
Not as reported. The authors requested recalled zero-to-ten pain ratings but did not report paired-score results, a prespecified responder definition, a hypothesis test, or a confidence interval for the improvement category.[1]
Did follow-up imaging show tissue repair?
No follow-up imaging or other structural measurement was reported. The four pre-procedure MRIs cannot establish subsequent repair.[1]
Were there no adverse events?
The authors said none were noted, but their retrospective telephone report was not comprehensive safety surveillance. FDA's later briefing judged the overall clinical safety information insufficient.[1][3]
Does this review validate a BPC-157 product or vial?
No. It cannot authenticate another material or transfer the findings across substance form, formulation, impurities, route, supplier, blend, or lot.
Primary and official sources
- Primary full article copy, Lee and Padgett, 2021, pages 8–13
- PubMed: PMID 34324435
- FDA BPC-157 briefing, May 11, 2026 memorandum for the July 23–24 meeting
- FDA: bulk substances that may present significant safety risks
- FDA July 23–24, 2026 meeting, agenda, advisory scope, and official materials
- FDA July 23, 2026 presentations, BPC-157 section
Review and corrections
Sources checked September 3, 2026 (America/Edmonton and UTC). Serum Research is responsible for this editorial summary. No independent clinical, statistical, analytical, or regulatory specialist review is claimed. This is nonmedical research interpretation, not treatment advice or a product-quality or equivalence conclusion.
See how we review evidence, browse the study records or research library, and contact us with a source correction.